IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium

Rhea-AI Summary

IceCure Medical participated in a cryoablation symposium in Thailand, showcasing its ProSense System. Professor Fukuma, who has performed over 600 procedures with ProSense, praised its effectiveness and minimal side effects. The partnership between IceCure and Terumo Thailand is expected to improve sales momentum. The growing data on ProSense's efficacy supports its use in treating breast, lung, and kidney tumors.

Positive

• Professor Fukuma's positive testimonial on ProSense's effectiveness and minimal side effects
• Partnership with Terumo Thailand expected to improve sales momentum

Negative

• None.

• Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense
• IceCure joined its exclusive regional distributor, Terumo, to exhibit the ProSense System to physicians seeking minimally invasive alternatives to lumpectomy  

CAESAREA, Israel, Aug. 21, 2023 /PRNewswire/ -- IceCure Medical LTD. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, recently participated in the 16^th Thai Breast Symposium in Bangkok, Thailand, which was hosted by the Thai Breast Surgeons Society. IceCure representatives, including VP of Business Development & Global Marketing, Tlalit Bussi Tel-Tzure, participated at Terumo Corporation's (Tokyo: 4543;US OTC: TRUMY) booth. Terumo is the Company's exclusive distributor of the ProSense System in Japan and Thailand.

A cryoablation symposium, "Cryoablation Emerging as Effective Treatment for Breast Cancer", was led by Professor Eisuke Fukuma, Director of the Breast Center at Kameda Medical Center, Japan.

Professor Fukuma commented, "I've performed over 600 breast tumor procedures with ProSense with excellent results. Patients have minimal pain, no change to the volume or the shape of the breast, and they can quickly resume their normal activities the day following the procedure. Because of this, many women come to my facility and seek out cryoablation. I am pleased to be here at the conference to inform and educate other doctors on how to use ProSense to benefit their patients."

Israel's Ambassador to Thailand, Orna Sagiv, added, "IceCure's breakthrough technology marks a new era in women's health treatment. This innovative solution to treat benign and malignant tumors allows for a safe and effective procedure without the trauma, pain, and scarring which has been inevitable until now. This technology represents a new hope for patients and their families facing a cancer diagnosis. The partnership between IceCure, an Israeli company, and Terumo Thailand is another manifestation of the Thai-Israeli potential for collaboration that will improve the lives of both Thais and Israelis. The Embassy of Israel supports this unique partnership and hopes it will help save many lives."

"The growing amount of data on ProSense's efficacy in treating tumors of the breast, lung, and kidney supports our sales momentum in Thailand since ProSense was approved to treat these cancers," stated Terumo Thailand's Managing Director, Panapon Chantakulchai. "Highlighting ProSense at the Thai Breast Society Symposium is very timely as the global medical community recognizes the benefits of this cost-efficient, non-invasive and effective option."

IceCure's Tlalit Bussi Tel-Tzure, commented, "We had very strong interest in ProSense both at the Terumo booth and at Professor Fukuma's talk. The awareness around cryoablation as a minimally invasive method to treat early-stage breast cancer continues to gain momentum and ProSense is extremely well positioned as the system of choice for breast surgeons. Terumo has been a great partner for us in Thailand where we expect to see growing sales momentum."

About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

Forward looking Statements

This press release contains forward looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal and Israeli securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward looking statements. For example, IceCure is using forward looking statement in this press release when it discusses that IceCure's breakthrough technology marks a new era in women's health treatment, that this technology represents a new hope for patients who face a cancer diagnosis, that the partnership between IceCure and Terumo Thailand will improve the lives of Thais and Israelis, that the ProSense System is well positioned as the system of choice for breast surgeons and that IceCure expects to see growing sales momentum in Thailand. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on March 29, 2023, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR Contact:
Michael Polyviou
Phone: 732-232-6914
Email: mpolyviou@evcgroup.com

Todd Kerhli
Phone: 310-625-4462
Email: tkehrli@evcgroup.com 

Logo - https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/icecure-medical-continues-to-experience-growing-global-interest-in-prosense-featured-at-the-16th-thai-breast-symposium-301905403.html

SOURCE IceCure Medical